81. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. (1st September 2018) Authors: Blauvelt, A.; Lacour, J.‐P.; Fowler, J.F.; Weinberg, J.M.; Gospodinov, D.; Schuck, E.; Jauch‐Lembach, J.; Balfour, A.; Leonardi, C.L. Journal: British journal of dermatology Issue: Volume 179:Number 3(2018) Page Start: 623 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
82. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. (9th December 2020) Authors: Golbari, N.M.; van der Walt, J.M.; Blauvelt, A.; Ryan, C.; van de Kerkhof, P.; Kimball, A.B. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 2(2021) Page Start: 417 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
83. Rapid improvements in health‐related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER‐2 and UNCOVER‐3. (28th June 2017) Authors: Leonardi, C.L.; Blauvelt, A.; Sofen, H.L.; Gooderham, M.; Augustin, M.; Burge, R.; Zhu, B.; Reich, K. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 31:Number 9(2017) Page Start: 1483 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
84. Reaching complete or near‐complete resolution of psoriasis: benefit and risk considerations. (1st August 2017) Authors: Blauvelt, A.; Griffiths, C.E.M.; Lebwohl, M.; Mrowietz, U.; Puig, L.; Ball, S.; Zhang, L.; Edson‐Heredia, E.; Warner, M.; Zhu, B.; Lin, C‐Y.; Nikaï, E.; Dey, D.; Mallbris, L.; Reich, K. Journal: British journal of dermatology Issue: Volume 177:Number 2(2017) Page Start: 587 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
85. Reaching complete or near‐complete resolution of psoriasis: benefit and risk considerations. (3rd July 2017) Authors: Blauvelt, A.; Griffiths, C.E.M.; Lebwohl, M.; Mrowietz, U.; Puig, L.; Ball, S.; Zhang, L.; Edson‐Heredia, E.; Warner, M.; Zhu, B.; Lin, C‐Y.; Nikaï, E.; Dey, D.; Mallbris, L.; Reich, K. Journal: British journal of dermatology Issue: Volume 177:Number 2(2017) Page Start: 587 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
86. Response to critical appraisal of LIBERTY AD CHRONOS. (14th October 2018) Authors: Blauvelt, A.; Shumel, B. Journal: British journal of dermatology Issue: Volume 179:Number 6(2018) Page Start: 1423 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
87. Response to critical appraisal of LIBERTY AD CHRONOS. (1st December 2018) Authors: Blauvelt, A.; Shumel, B. Journal: British journal of dermatology Issue: Volume 179:Number 6(2018) Page Start: 1423 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
88. Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials. (1st September 2018) Authors: Blauvelt, A.; Reich, K.; Papp, K.A.; Kimball, A.B.; Gooderham, M.; Tyring, S.K.; Sinclair, R.; Thaçi, D.; Li, Q.; Cichanowitz, N.; Green, S.; La Rosa, C. Journal: British journal of dermatology Issue: Volume 179:Number 3(2018) Page Start: 615 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
89. Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials. (4th July 2018) Authors: Blauvelt, A.; Reich, K.; Papp, K.A.; Kimball, A.B.; Gooderham, M.; Tyring, S.K.; Sinclair, R.; Thaçi, D.; Li, Q.; Cichanowitz, N.; Green, S.; La Rosa, C. Journal: British journal of dermatology Issue: Volume 179:Number 3(2018) Page Start: 615 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
90. Secukinumab administration by pre‐filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). (11th December 2014) Authors: Blauvelt, A.; Prinz, J.C.; Gottlieb, A.B.; Kingo, K.; Sofen, H.; Ruer‐Mulard, M.; Singh, V.; Pathan, R.; Papavassilis, C.; Cooper, S.; the FEATURE Study Group Journal: British journal of dermatology Issue: Volume 172:Number 2(2015:Feb.) Page Start: 484 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗